These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 11575701

  • 1. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
    Naeger LK, Miller MD.
    Curr Opin Investig Drugs; 2001 Mar; 2(3):335-9. PubMed ID: 11575701
    [Abstract] [Full Text] [Related]

  • 2. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V, Larder BA.
    Antivir Ther; 2001 Mar; 6 Suppl 3():25-44. PubMed ID: 11678471
    [Abstract] [Full Text] [Related]

  • 3. K65R, TAMs and tenofovir.
    Miller MD.
    AIDS Rev; 2004 Mar; 6(1):22-33. PubMed ID: 15168738
    [Abstract] [Full Text] [Related]

  • 4. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
    Miller MD, Margot NA, Hertogs K, Larder B, Miller V.
    Nucleosides Nucleotides Nucleic Acids; 2001 Mar; 20(4-7):1025-8. PubMed ID: 11562951
    [Abstract] [Full Text] [Related]

  • 5. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM, Merigan TC, Winters MA, Heseltine PN.
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract] [Full Text] [Related]

  • 6. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S, Baldanti F, Campanini G, Cancio R, Belfiore A, Maga G, Gerna G.
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [Abstract] [Full Text] [Related]

  • 7. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.
    Selmi B, Deval J, Boretto J, Canard B.
    Antivir Ther; 2003 Apr; 8(2):143-54. PubMed ID: 12741627
    [Abstract] [Full Text] [Related]

  • 8. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
    Marchand B, White KL, Ly JK, Margot NA, Wang R, McDermott M, Miller MD, Götte M.
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2911-9. PubMed ID: 17517852
    [Abstract] [Full Text] [Related]

  • 9. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L, Henry K, Paar D, Salvato P, Shaefer M, Fisher R, Liao Q, St Clair M.
    J Hum Virol; 2001 Aug; 4(4):217-22. PubMed ID: 11694850
    [Abstract] [Full Text] [Related]

  • 10. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V.
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [Abstract] [Full Text] [Related]

  • 11. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [Abstract] [Full Text] [Related]

  • 12. Tenofovir disoproxil fumarate.
    Gallant JE, Deresinski S.
    Clin Infect Dis; 2003 Oct 01; 37(7):944-50. PubMed ID: 13130407
    [Abstract] [Full Text] [Related]

  • 13. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C, Jiménez-Nacher I, Garrido C, Barreiro P, Poveda E, Corral A, Zahonero N, González-Lahoz J, Soriano V.
    Clin Infect Dis; 2008 Jun 01; 46(11):1782-5. PubMed ID: 18426370
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW.
    AIDS; 2007 Jul 11; 21(11):1405-14. PubMed ID: 17589186
    [Abstract] [Full Text] [Related]

  • 15. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
    Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, Micheli V, Brenner BG.
    Antimicrob Agents Chemother; 2007 Nov 11; 51(11):3861-9. PubMed ID: 17724152
    [Abstract] [Full Text] [Related]

  • 16. Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.
    Naeger LK, Margot NA, Miller MD.
    Nucleosides Nucleotides Nucleic Acids; 2001 Nov 11; 20(4-7):635-9. PubMed ID: 11563081
    [Abstract] [Full Text] [Related]

  • 17. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S, Otelea D, Baicus C, Tinischi M, Costache M, Neaga E.
    Int J Infect Dis; 2009 Jan 11; 13(1):81-9. PubMed ID: 18632295
    [Abstract] [Full Text] [Related]

  • 18. The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants.
    Boyer PL, Julias JG, Ambrose Z, Siddiqui MA, Marquez VE, Hughes SH.
    J Mol Biol; 2007 Aug 24; 371(4):873-82. PubMed ID: 17597154
    [Abstract] [Full Text] [Related]

  • 19. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.
    Ray AS, Murakami E, Basavapathruni A, Vaccaro JA, Ulrich D, Chu CK, Schinazi RF, Anderson KS.
    Biochemistry; 2003 Jul 29; 42(29):8831-41. PubMed ID: 12873144
    [Abstract] [Full Text] [Related]

  • 20. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
    Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R.
    Antiviral Res; 2005 Jul 29; 67(1):1-9. PubMed ID: 15890415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.